Lack of clarity over Teva Pharmaceutical Industries Ltd.'s liability in ongoing opioid litigation continues to weigh on the generic drug manufacturer as it works toward a financial turnaround. Despite executing on a sweeping cost savings program, continuing to pay down on a mountain of debt and progress stabilizing its North American generic drug business, the company's growth trajectory remains unclear.
Opioid Litigation Clouds Loom Over Teva's Turnaround
Increasing uncertainty over Teva's liability in opioid litigation is weighing on the generic drug manufacturer, even as the North American generics business stabilized in the second quarter.
More from Earnings
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.